Rosetta Genomics (ROSG) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as climbing oil, yields amplify inflation fears
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- CoreWeave stock drops on dilution fears and debt concerns
Rosetta Genomics Reports 2016 First Quarter Financial Results
May 19, 2016 8:01 AM EDTRecord Quarterly Clinical Testing Revenues of $2.6 million
Conference call begins today at 10:00 a.m. Eastern time
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three months ended March 31, 2016.
Recent developments include:
Expanded molecular diagnostics test menu with the launch of three new product offerings in common hematologic cancers and solid tumors; Received conditional approval status from... More


